-
Dec 2, 2024 | 
optometrytimes.com | A. Paul Chous
December 2, 2024By Optometry Times JournalNovember digital edition 2024Studies point to an inverse association between diabetes and keratoconus risk.
-
Nov 22, 2024 | 
optometrytimes.com | A. Paul Chous |Emily Kaiser Maharjan |Jordana Joy
November 22, 2024By According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes. A. Paul Chous, MA, OD, FAAO, provides some takeaways from the "Diabetes Update: What's New in 2024" presentation given at the American Academy of Optometry meeting. Editor's note: The below transcript has been lightly edited for clarity.
-
Nov 21, 2024 | 
optometrytimes.com | A. Paul Chous |Emily Kaiser Maharjan |Jordana Joy
November 21, 2024By A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting. Paul Chous, MA, OD, FAAO, overviews a presentation he gave at the 2024 American Academy of Optometry meeting alongside Jeffry Gerson, OD, FAAO. Chous explains that the presentation will focus on several key updates in diabetes care, including a greater emphasis on racial and socioeconomic disparities in diabetic eye disease.
-
Aug 13, 2024 | 
optometrytimes.com | A. Paul Chous
August 13, 2024By It’s time to act with a few rational and relatively modest proposals. Substantial research shows significant racial and class disparities in diabetes care and outcomes.
-
May 20, 2024 | 
optometrytimes.com | A. Paul Chous
May 20, 2024Optometry Times JournalMay digital edition 2024Amid conflicting findings, factors such as dosage, patient characteristics may affect outcomes. Controversy surrounds the potential benefits of omega-3 polyunsaturated fatty acid (PUFA) supplementation for a variety of ophthalmic conditions linked to diabetes, including ocular surface disease and diabetic retinopathy.
-
Mar 22, 2024 | 
evolvemeded.com | Roger A. Goldberg |A. Paul Chous |Joseph W. Sowka
Upon completion of this activity, the participant should be able to: Review advances in current treatments for diabetic eye disease and nAMD Identify patients who may benefit from advances in the treatment paradigm for retinal vascular diseases Formulate strategies to identify and resolve barriers to optimal treatment outcomes for patients with nAMD and diabetic eye disease Summarize therapies for retinal vascular diseases that are in clinical development Evolve Medical Education LLC (Evolve)...
-
Feb 12, 2024 | 
optometrytimes.com | A. Paul Chous
February 12, 2024Optometry Times JournalFebruary digital edition 2024This article outlines which medications may be best to take to mitigate the onset of type 2 diabetes through weight loss, in addition to lessening sugar intake and other eating habits. Risk of type 2 diabetes (T2D) has long been associated with overweight and obesity.
-
Nov 14, 2023 | 
optometrytimes.com | A. Paul Chous
When eye doctors think about metabolic disturbances caused by diabetes and the risk of eye disease, chronically elevated blood glucose levels that damage the retina often come to mind. Hyperglycemic insult to both vascular and neural elements of the retina has strongly been linked in multiple laboratory and clinical studies to the development and progression of diabetic retinal disease.1 But what about the antithesis of hyperglycemia—hypoglycemia?
-
Aug 28, 2023 | 
optometrytimes.com | A. Paul Chous
Aug 28, 2023Optometry Times JournalAugust digital edition 2023T1D is one of the most common chronic diseases affecting pediatric populations.
-
Jul 28, 2023 | 
optometrytimes.com | A. Paul Chous |Emily Kaiser |Marlisa Miller
A. Paul Chous, OD, MA, FAAO, co-chair of the 2023 EyeCon meeting, caught up with Optometry Times®' assistant managing editor, Emily Kaiser, to share the exciting things he's looking forward do for this year's meeting. The third annual EyeCon meeting will be held December 1-2, 2023, at the Marriott Sanibel Harbour Resort & Spa in Sanibel Harbour, Florida. To learn more about the meeting and register, visit PER's website here. TranscriptEditor's note: This transcript has been edited for clarity.
